The inactivation of human plasma kallikrein (EC 3.4.21.8) by the inhibitor of activated complement component 1 (C1 inhibitor) induces the formation of a 1:1 stoichiometric kallikrein-C1 inhibitor complex and a proteolytically modified form of C1 inhibitor. We have produced a monoclonal antibody that recognizes the kallikrein-C1 inhibitor complex as well as modified C1 inhibitor but fails to react with virgin C1 inhibitor or native plasma kallikrein. This observation constitutes an unequivocal demonstration that the reaction between plasma kallikrein and C1 inhibitor leads to the emergence of an epitope that is undetectable on the parent enzyme and inhibitor molecules.
No takes yet. Share an insight, caveat, or question.
Agostini et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: